本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
Pharmstandard International S.A. (CIK 1598762) reported $29.0M across 6 reported positions in its SEC 13F filing for 2018-09-30. Largest positions: ALNAQ ($9.4M, 32.28%), PTGX ($7.7M, 26.59%), NTGN ($5.0M, 17.31%), JNCE ($3.7M, 12.65%), TARA ($3.1M, 10.79%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ALNAQ | Allena Pharmaceuticals | $9.4M | 32.28% | 873,031 | Trimmed |
| 2 | PTGX | Protagonist Therapeutics, Inc. | $7.7M | 26.59% | 750,632 | Hold |
| 3 | NTGN | Neon Therapeutics Inc. | $5.0M | 17.31% | 588,611 | New |
| 4 | JNCE | Jounce Therapeutics, Inc. | $3.7M | 12.65% | 565,063 | Hold |
| 5 | TARA | Proteon Therapeutics Inc. | $3.1M | 10.79% | 1.6M | Hold |
| 6 | ARGSQ | Argos Therapeutics Inc. | $109,000 | 0.38% | 1.1M | Hold |
来源：SEC 13F 申报文件 · 截至 2018-09-30